Collectively, our findings highlight the prominent role of nSMase2 in hepatic steatosis, which could serve as a potential therapeutic target for NAFLD and other hepatic steatosis-linked disorders. The gene discussed is SMPD3; the disease is metabolic dysfunction-associated steatotic liver disease.